Skip to main content

Advertisement

Table 1 Correlation between TATI serum levels and clinicopathological characteristics

From: Increased serum levels of tumour-associated trypsin inhibitor independently predict a poor prognosis in colorectal cancer patients

Categories calculated via ROC-curve: < 15.59 > 15.59 total P-value missing
Ranges (s-TATI μg/l) 4.346-15.587 15.588-168.570    
n(%) 192(59.3) 132(40.7) 324(100)   
Age      
< 75 129(69.7) 50(40.7) 179(58.1)   
≥75 56(30.3) 73(59.3) 129(41.9) < 0.001** 16(4.9)
Gender      
Female 90(46.9) 71(53.8) 161(49.7)   
Male 102(53.1) 61(46.2) 163(50.3) 0.289 0(0.0)
Disease stage      
I 26(13.7) 18(13.8) 44(13.8)   
II 84(44.2) 50(38.5) 134(41.9)   
III 58(30.5) 37(28.5) 95(29.7)   
IV 22(11.6) 25(19.2) 47(14.7) 0.284 4(1.2)
Differentiation grade      
High-moderate 155(80.7) 95(74.2) 250(78.1)   
Poor 37(19.3) 33(25.8) 70(21.9) 0.168 4(1.2)
Vascular invasion      
No invasion 164(88.6) 106(86.2) 270(87.7)   
Invasion 21(11.4) 17(13.8) 38(12.3) 0.519 16(4.9)
Mucinous or non-mucinous      
Non mucinous tumour 161(87.0) 106(86.2) 267(86.7)   
Mucinous tumour 24(13.0) 17(13.8) 41(13.3) 0.830 16(4.9)
Colon or rectal cancer      
Colon cancer 115(59.6) 102(77.9) 217(67.0)   
Rectal cancer 78(40.4) 29(22.1) 107(33.0) 0.001 0(0)
Colon left or right ex ca recti      
Right colon 58(50.4) 64(63.4) 122(56.2)   
Left colon 57(49.6) 37(36.6) 94(43.5) 0.056 1(0.5)
CEA serum      
< 2,67 μg/L 101(52.6) 57(43.2) 158(48.8)   
≥ 2,67 μg/L 91(47.4) 75(56.8) 166(51.2) 0.095 0(0)
Preop radiation therapy      
Received 129(66.8) 110(84.0) 239(73.8)   
Not received 64(33.2) 21(16.0) 85(26.2) 0.001 0(0)
TATI expression in tissue      
< 50% 145(81.0) 87(73.7) 232(78.1)   
≥ 50% 34(19.0) 31(26.3) 65(21.9) 0.138 27(8.3)